



Table of Contents

MEK1-luc and KSR1-luc steady-state IC50 replicate curves (Figure 2).....	2
MEK1-luc Washout replicates plotted at different MEKi concentrations (Figure 2).....	3
MEK1-luc Washout replicates plotted for each MEKi (Figure 2).....	4
KSR1-luc Washout replicates plotted at different MEKi concentrations (Figure 2).....	5-6
KSR1-luc Washout replicates plotted for each MEKi (Figure 2).....	7
Washout experiments performed at saturating MEKi for MEK1-luc and KSR1-luc.....	8
RET-luc, Src-luc, and KSR1-W781D-luc Trametinib dose-responses (Extended Data Figure 4).....	9
MEK1-luc + KSR1 WT/W781D co-expression steady-state IC50 replicate curves (Extended Data Figure 5).....	10
Trametinib dose-response on MEK1 co-expressions, Tram-bo wash-in on MEK1 co-expressions, and Tram-bo BRET buildup curves for ARAF-luc, BRAF-luc, CRAF-luc, hKSR1-luc, and hKSR2-luc (Extended Data Figure 5 and Extended Data Figure 7)	11



	Independent replicate 1				
Trametinib (μ M)	plate 1	plate 2	plate 3	plate 4	
KSR1-luc	0.007069	0.007545	0.005778	0.00464	
MEK1-luc	0.005249	0.006208	0.006681	0.01084	

MEK1(µM)	Ind. Rep 1	Ind. Rep 2	Ind. Rep 3	Average	S.E.M.
Trametigibe	0.0352	0.0296	0.0300	0.0316	0.0018
CH5126766	6.1620	2.8820	3.8050	4.2830	0.9766
PD0325901	0.0748	0.0588	0.0746	0.0694	0.0053
Cobimetinib	0.0987	0.0961	0.1137	0.1028	0.0055
Selumetinib	4.9150	3.6600	7.3450	5.3067	1.0816



Plotted data and error bars represent the mean and SEM of three technical replicates except for Tramelinib, which is four technical replicates


Washout on MEK1-luc reporter

Cells were pre-treated with the indicated concentration for each MEKi, washed with Opti-MEM, and BRET signal was measured for 175 min upon the addition of Tram-bo and the Nanoluc substrate furimazine. Related to Figure 2. Each independent replicate was conducted in technical duplicates.

Independent Replicate 1


Independent Replicate 2

Independent Replicate 3




Washout on MEK1-luc reporter: data replotted from page 3 as a function of concentration


Independent Replicate 1




Independent Replicate 2




Independent Replicate 3




Trametiglue




Trametiglue




Trametiglue




CH5126766




CH5126766




CH5126766




PD0325901




PD0325901




PD0325901




Cobimetinib




Cobimetinib




Cobimetinib




Selumetinib



Selumetinib




Selumetinib




Washout on KSR1-luc reporter

Cells were pre-treated with the indicated concentration for each MEKi, washed with Opti-MEM, and BRET signal was measured for 175 min upon the addition of Tram-bo and the Nanoluc substrate furimazine. Related to Figure 2. Each replicate was conducted in technical duplicates.


Independent Replicate 1




Independent Replicate 2




Independent Replicate 3




25 nM




25 nM




25 nM




12.5 nM




12.5 nM




12.5 nM




6.25 nM



6.25 nM




6.25 nM




Washout on KSR1-luc reporter

Cells were pre-treated with the indicated concentration for each MEKi, washed with Opti-MEM, and BRET signal was measured for 175 min upon the addition of Tram-bo and the Nanoluc substrate furimazine. Related to Figure 2. Each replicate was conducted in technical duplicates.




Washout on KSR1-luc reporter: data replotted from page 5 as a function of concentration


Independent Replicate 1




Independent Replicate 2




Independent Replicate 3




Trametiglue




Trametiglue




Trametiglue




CH5126766




CH5126766




CH5126766




PD0325901




PD0325901




PD0325901




Cobimetinib




Cobimetinib




Cobimetinib




Selumetinib



Selumetinib




Selumetinib




MEK1-luc

wash




no-wash




KSR1-luc

wash



no-wash




Comparison of tram-bo wash-in buildup curves on cells pre-treated at 15x the IC₅₀ for each MEKi. Cells were either washed with Opti-MEM to remove excess drug (wash) or directly assayed (no-wash) upon the addition of tram-bo and the Nano-luc substrate furimazine. Data and error bars represent the mean and SEM of technical triplicates. The lack of build-up signal under no-wash conditions demonstrates that MEK1-luc and KSR1-luc were completely saturated with each MEKi. However, given the potency of several MEKi (i.e. no build-up over 175 min), lower concentrations of those MEKi were used to distinguish variances in MEKi off-rates or residence time (pages 2 and 4).


Drug	Saturating Concentration
Trametinib	100 nM
Trametiglue	100 nM
CH5126766	100 μM
PD0325901	1 μM
Cobimetinib	2 μM
Selumetinib	10 μM

RET-luc + Tram-bo (1 μ M)


Independent Replicate 1



Independent Replicate 2




Independent Replicate 3




Src-luc + Tram-bo (1 μ M)


Independent Replicate 1



Independent Replicate 2




Independent Replicate 3




The lack of dose-responses of control kinases (RET and SRC-luc) reveal that tram-bo specifically generates BRET dose on MEK1-luc and KSR1-luc. Related to Extended Data Figure 4. Data represent the average of duplicate technical replicates.

KSR1-luc W781D + Tram-bo (1 μ M)


Independent Replicate 1




Independent Replicate 2



Independent Replicate 3



The lack of dose-responses on KSR1-W781D-luc reveals that tram-bo specifically generates BRET dose on the MEK1-KSR1-complex. Data represent the average of duplicate technical replicates.




MEK1-luc + KSR1-WT (μM)	ind. rep. 1	ind. rep. 2	ind. rep. 3	Average	SEM
Trametinib	0.00429	0.01003	0.01455	0.00962333	0.00296878
Trametiglue	0.004731	0.009799	0.01782	0.01078333	0.00381039
CH5126766	4.167	8.029	12.25	8.1486667	2.33412813
PD325901	0.0224	0.03817	0.06024	0.04027	0.01097382
Cobimetinib	0.004868	0.01346	0.01183	0.01005267	0.00263469
Selumetinib	0.6553	1.162	1.357	1.0581	0.20911889


Plotted data represent the mean of duplicate technical replicates

Comparison of Trametinib dose-response curves on different MEK1 co-expressions
 (Related to Extended Data Figure 5). Data and error bars represent the mean duplicate technical replicates.


Independent Replicate 1



Independent Replicate 2




Independent Replicate 3




Comparison of Tram-bo wash-in buildup curves on different MEK1 co-expressions
 (Related to Extended Data Figure 5) Data and error bars represent the mean and SEM of three technical replicates.


Independent Replicate 1



Independent Replicate 2




Independent Replicate 3




Tram-bo Buildup Curves for ARAF-luc, BRAF-luc, CRAF-luc, hKSR1-luc, and hKSR2-luc
 (Related to Extended Data Figure 5) Data represent the mean of duplicate technical replicates.

Independent Replicate 1



Independent Replicate 2



Independent Replicate 3

